Journal for ImmunoTherapy of Cancer (Nov 2021)
529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
- Rebecca Kristeleit,
- Howard Burris,
- Kristen Spencer,
- Sarina Piha-Paul,
- Hans Prenen,
- Tara Mitchell,
- David Pinato,
- Solmaz Sahebjam,
- Donna Graham,
- Nuria Kotecki,
- Eric Van Cutsem,
- Brant Delafontaine,
- Thomas Karasic,
- Jeannie Daniel,
- Kevin O’Hayer,
- Ryan Geschwindt
Affiliations
- Rebecca Kristeleit
- 2 Gynaecological Oncology, University College London Hospitals NHS Foundation Trust, London, UK
- Howard Burris
- 2SCRI, Nashville, TN, USA
- Kristen Spencer
- Aff2 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey 195 Little Albany Street 08901 New Brunswick NJ USA
- Sarina Piha-Paul
- 1MD Anderson Cancer Center, Houston, TX, USA
- Hans Prenen
- Department of Medical Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium
- Tara Mitchell
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- David Pinato
- 3Imperial College London, London, UK
- Solmaz Sahebjam
- Department of Neuro-oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
- Donna Graham
- The Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK
- Nuria Kotecki
- 7Institut Jules Bordet, Brussels, Belgium
- Eric Van Cutsem
- 1University of Leuven, Leuven, Belgium
- Brant Delafontaine
- 3Ghent University Hospital, Ghent, Belgium
- Thomas Karasic
- 5University of Pennsylvania, Philadelphia, PA, USA
- Jeannie Daniel
- 12Incyte Corporation, Wilmington, DE, USA
- Kevin O’Hayer
- 12Incyte Corporation, Wilmington, DE, USA
- Ryan Geschwindt
- 12Incyte Corporation, Wilmington, DE, USA
- DOI
- https://doi.org/10.1136/jitc-2021-SITC2021.529
- Journal volume & issue
-
Vol. 9,
no. Suppl 2
Abstract
No abstracts available.